Kaliumchlorid Lösung Noridem

Potassium chloride, the active ingredient in Kaliumchlorid Lösung Noridem, is an electrolyte presented as an injectable solution for intravenous use. It treats hypokalemia and provides potassium supplementation during intravenous therapy in hospitalized patients.

GNH USA supplies Kaliumchlorid Lösung Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Kaliumchlorid Lösung Noridem is used to correct potassium deficits and support electrolyte balance in clinical settings.

- Hypokalemia: restores normal plasma potassium concentrations in patients with low serum potassium. - Intravenous potassium supplementation: maintains electrolyte homeostasis during IV fluid therapy. - Prevention of cardiac arrhythmias in potassium‑deficient patients: supports normal cardiac electrical activity.

Kaliumchlorid Lösung Noridem may be associated with several adverse reactions.

Common Side Effects: - Injection site pain or irritation. - Mild nausea or vomiting. - Transient hyperkalemia symptoms such as tingling. - Headache.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Anaphylactic or severe allergic reaction. - Phlebitis or thrombophlebitis at the infusion site. - Electrolyte imbalance causing muscle weakness or paralysis.

When using Kaliumchlorid Lösung Noridem, clinicians should consider several safety measures.

- Patient assessment: verify serum potassium levels before administration. - Infusion rate: avoid rapid infusion to reduce risk of hyperkalemia. - Cardiac monitoring: observe ECG for arrhythmias during and after infusion. - Drug compatibility: check compatibility with other IV solutions. - Renal function: adjust dose in patients with impaired renal clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potassium chloride can interact with several medications that affect potassium balance.

Major Interactions (Avoid): - ACE inhibitors or ARBs: may potentiate hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of elevated serum potassium. - NSAIDs: can reduce renal potassium excretion.

Moderate Interactions (Monitor Closely): - Digoxin: hyperkalemia can enhance digoxin toxicity. - Beta‑blockers: may mask symptoms of hypoglycemia and affect potassium levels. - Insulin or glucose therapy: can shift potassium intracellularly, requiring monitoring.